NASDAQ:INCY Incyte Q3 2026 Earnings Report $123.20 -1.62 (-1.30%) Closing price 09/29/2026 04:00 PM EasternExtended Trading$122.98 -0.22 (-0.17%) As of 07:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Incyte EPS ResultsActual EPSN/AConsensus EPS -$2.79Beat/MissN/AOne Year Ago EPSN/AIncyte Revenue ResultsActual RevenueN/AExpected Revenue$1.47 billionBeat/MissN/AYoY Revenue GrowthN/AIncyte Announcement DetailsQuarterQ3 2026Date10/27/2026TimeBefore Market OpensConference Call DateTuesday, October 27, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Incyte Earnings HeadlinesIncyte Corporation (NASDAQ:INCY) Receives Average Recommendation of "Moderate Buy" from Brokerages4 hours ago | americanbankingnews.comIncyte’s KRAS G12D Lead Supports Undervalued Upside as Kapoor Reiterates Buy and Maintains $152 Price TargetSeptember 29 at 6:51 AM | tipranks.comDr. Ron Paul Issues New Warning: “The Next Financial Crisis Is Here”Dr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dollars and roughly 30 U.S. companies. Some stocks tied to this shift have already fallen 50% or more, Paul says, as the relationship between government and the stock market changes.September 30 at 1:00 AM | Altimetry (Ad)Mirum’s Brellovitug Phase 3 Success Signals Transformational GrowthSeptember 28 at 9:10 AM | tipranks.comMiniMed appoints Sheila Denton as General Counsel & Corporate SecretarySeptember 28 at 9:03 AM | prnewswire.comIncyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDASeptember 28 at 8:17 AM | marketscreener.comMSee More Incyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Incyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Incyte and other key companies, straight to your email. Email Address About IncyteIncyte (NASDAQ:INCY) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases, with an emphasis on oncology, hematology and inflammatory or dermatologic conditions. The company conducts research through internal programs and collaborations with academic institutions, biotechnology companies and pharmaceutical partners. Incyte’s marketed portfolio includes Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain myelofibrosis, polycythemia vera and graft-versus-host disease indications, and Opzelura (ruxolitinib) cream for certain inflammatory skin conditions. Its portfolio also includes Pemazyre (pemigatinib), a targeted therapy for selected cancers with specific fibroblast growth factor receptor alterations. Incyte continues to develop additional therapies in oncology, immunology and dermatology. Founded in 1991, Incyte is headquartered in Wilmington, Delaware, and serves patients in the United States and international markets through its own commercial operations and partnerships. The company’s products may be marketed under different brand names or by collaborators outside the United States. Incyte is led by President and Chief Executive Officer Hervé Hoppenot.View Incyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
